title: [Pharmacological and clinical profile of once weekly alendronate for the treatment of osteoporosis (Fosamac 35 mg/Bonalon 35 mg)].
authors.affiliation: shinji_uchida@merck.com
authors.forename: Shinji
authors.initials: S
authors.lastname: Uchida
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Azuma
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Taniguchi
authors.forename: Hironori
authors.initials: H
authors.lastname: Arizono
authors.forename: Takafumi
authors.initials: T
authors.lastname: Shimizu
authors.forename: Masahiko
authors.initials: M
authors.lastname: Okaniwa
authors.forename: Keisuke
authors.initials: K
authors.lastname: Nakamura
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ohta
mesh_terms: D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001862:Bone Resorption; D001842:Bone and Bones / Q000378:metabolism; D004311:Double-Blind Method; D004947:Esophagus / Q000187:drug effects; D005260:Female; D006801:Humans; D008798:Mevalonic Acid / Q000378:metabolism; D010010:Osteoclasts / Q000187:drug effects / Q000378:metabolism; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D050071:Bone Density Conservation Agents; D008798:Mevalonic Acid; D019386:Alendronate